SCCA Clinical Trials: Group Health

The affiliation between SCCA and Group Health means that patients throughout the Group Health system will have access to the latest cancer treatment options, including those only available in clinical trials or at a comprehensive academic cancer center, such as SCCA. The following SCCA clinical trials are now available at Group Health:

Breast Cancer (Newly Diagnosed)

• WBI Versus PBI for Women with Stage 0, I or II Breast Cancer (NSABP B-39)
  A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) Versus Partial Breast Irradiation (PBI) for Women with Stage 0, I or II Breast Cancer
• Herceptin + Radiation Therapy for HER2-Positive Resected by Lumpectomy (NSABP B-43)
  A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently With Radiation Therapy and Radiation Therapy Alone for Women With HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy

Gynecologic Cancer (Newly Diagnosed)

• Paclitaxel vs Polyglutamate Paclitaxel (GOG 212)
  A Randomized Phase III Trial of Maintenance Chemotherapy Comparing 12 Monthly Cycles of Single Agent Paclitaxel or Xyotax (CT-2103) (IND# 70177), Versus No Treatment Until Documented Relapse in Women With Advanced Ovarian or Primary Peritoneal or Fallopian Tube Cancer Who Achieve a Complete Clinical Response to Primary Platinum/Taxane Chemotherapy
• Radiation vs Brachytherapy for Endometrial Carcinoma (GOG 249)
  A Phase III Trial of Pelvic Radiation Therapy Versus Vaginal Cuff Brachytherapy Followed By Paclitaxel/Carboplatin Chemotherapy in Patients With High Risk, Early Stage Endometrial Carcinoma
• Paclitaxel + Carboplatin vs Ifosfamide + Paclitaxel for Uterine or Ovarian Cancer (GOG 261)
  A Randomized Phase III Trial of Paclitaxel plus Carboplatin versus Ifosfamide plus Paclitaxel in Chemotherapy-Naïve Patients with Newly Diagnosed Stage I-IV, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus or Ovary
• Temsirolimus + Carboplatin/Paclitaxel Stage III-IV Clear Cell Carcinoma of the Ovary (GOG 268)
  A Phase II Evaluation of Temsirolimus (CCI-779) (NCI Supplied Agent: NSC#683864, IND#61010) in Combination with Carboplatin and Paclitaxel followed by Temsirolimus (CCI-779) Consolidation as First-Line Therapy in the Treatment of Stage III-IV Clear Cell Carcinoma of the Ovary

Gynecologic Cancer (Recurrent/Metastatic)

• Paclitaxel vs Polyglutamate Paclitaxel (GOG 212)
  A Randomized Phase III Trial of Maintenance Chemotherapy Comparing 12 Monthly Cycles of Single Agent Paclitaxel or Xyotax (CT-2103) (IND# 70177), Versus No Treatment Until Documented Relapse in Women With Advanced Ovarian or Primary Peritoneal or Fallopian Tube Cancer Who Achieve a Complete Clinical Response to Primary Platinum/Taxane Chemotherapy
• Carboplatin + Paclitaxel w/wo Bevacizumab After Surgery (GOG 213)
  A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel Alone or in Combination With Bevacizumab (NSC #704865, IND #7921) Followed by Bevacizumab and Secondary Cytoreduction Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer
• Combination Chemotherapy + Radiation Therapy for Stage III/IVA Endometrial Cancer (GOG 0258)
  A Randomized Phase III Trialof Cisplatin and Tumor Volume Directional Irradiation Followed By Carboplatin and Paclitaxel Vs.for Optimally Debulked, Advanced Endometrial Carcinoma
• Elesclomol Sodium and Paclitaxel for Recuyrrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer (GOG 260)
  A Phase II Evaluation of Elesclomol Sodium and Weekly Paclitaxel in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer
• Paclitaxel + Carboplatin vs Ifosfamide + Paclitaxel for Uterine or Ovarian Cancer (GOG 261)
  A Randomized Phase III Trial of Paclitaxel plus Carboplatin versus Ifosfamide plus Paclitaxel in Chemotherapy-Naïve Patients with Newly Diagnosed Stage I-IV, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus or Ovary
• Chemotherapy + Pelvic Radiation for High-Risk Early-Stage Cervical Cancer (GOG/ RTOG 0724)
  Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy with or Without Adjuvant Chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma Following Radical Hysterectomy